CombiPatch® Hormone Therapy

For your menopausal patients who require combination hormone therapy (HT),

Provide a Simple-to-Use, Effective HT With CombiPatch

CombiPatch utilizes Delivery Optimized Thermodynamics (DOT) Matrix®, a patented transdermal delivery system, to avoid first-pass hepatic metabolism and achieve therapeutic hormone levels with smaller daily doses compared to oral regimens. This does not imply differences in safety or efficacy. CombiPatch is indicated for women with an intact uterus for the treatment of moderate to severe symptoms associated with menopause.

Designed to provide a choice of dosing and regimen options with smaller daily doses as compared to orals*

CombiPatch provides your patients with a convenient transdermal option while giving you two dosing options and two approved treatment regimens to address their needs as they progress toward amenorrhea—Continuous Combined therapy with CombiPatch and Continuous Sequential therapy with CombiPatch and Vivelle-Dot® (estradiol transdermal system). These options allow you to respond to your patients' changing needs and address concerns they may have about breakthrough bleeding.

Learn more about The CombiPatch Difference.

*This does not imply differences in safety or efficacy.

CombiPatch ISI CombiPatch ISI CombiPatch ISI Full Prescribing Information for CombiPatch Full Prescribing Information for CombiPatch Full Prescribing Information for CombiPatch
Vivelle-Dot ISI Vivelle-Dot ISI Vivelle-Dot ISI Full Prescribing Information for Vivelle-Dot Full Prescribing Information for Vivelle-Dot Full Prescribing Information for Vivelle-Dot
Indication and Important Safety Information for CombiPatch Indication and Important Safety Information for Vivelle-Dot
Close X
Leaving the CombiPatch® Web Site

You are now leaving the CombiPatch Web site and moving to an external Web site independently operated and not managed by Novogyne Pharmaceuticals. Novogyne assumes no responsibility for the content of the site.

Continue
Close X
Leaving the CombiPatch® Web Site

You are now leaving the CombiPatch Web site and moving to an external Web site operated by Noven Pharmaceuticals, Inc., a partner with Novartis Pharmaceuticals Corporation in the joint venture Novogyne Pharmaceuticals.

Continue
Close X
Leaving the CombiPatch® Web Site

You are now leaving the CombiPatch Web site and moving to an external Web site operated by Novartis Pharmaceuticals Corporation, a partner with Noven Pharmaceuticals, Inc. in the joint venture Novogyne Pharmaceuticals.

Continue